![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1616710
½É¹æ¼¼µ¿ µð¹ÙÀ̽º ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)Atrial Fibrillation Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
¼¼°èÀÇ ½É¹æ¼¼µ¿ µð¹ÙÀ̽º ½ÃÀåÀº 2023³â¿¡ 106¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â CAGR 11.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ °ß°íÇÑ ¼ºÀåÀº ÁÖ·Î ½É¹æ¼¼µ¿ ÀåºñÀÇ ¹ßÀü, ½É¹æ¼¼µ¿ À¯º´·ü Áõ°¡, ½ÉÀå ÀýÁ¦¼úÀÇ Ã¤Åà Áõ°¡, Á¶±â Áø´ÜÀ¸·Î À̾îÁö´Â ÀÎ½Ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ½É¹æ¼¼µ¿ ¹ß»ý·üÀº Àü ¼¼°è¿¡¼ Áõ°¡ Ãß¼¼¿¡ ÀÖÀ¸¸ç, ½ÉÀå ºÎÁ¤¸Æ Áß °¡Àå ÈçÇÑ À¯ÇüÀÌ µÇ¾ú½À´Ï´Ù. Àα¸ °í·ÉÈ, ºñ¸¸, °íÇ÷¾Ð ¹× ±âŸ ½ÉÇ÷°ü°è Áúȯ Áõ°¡·Î ÀÎÇØ ½É¹æ¼¼µ¿ ¹ß»ý·üÀÌ Àü ¼¼°è¿¡¼ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼ ¼ö¹é¸¸ ¸íÀÌ ÀÌ ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, Áø´Ü ¹× Ä¡·á Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½É¹æ¼¼µ¿¿¡ ´ëÇÑ È¯ÀÚ¿Í ÀÇ·áÁøÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½É¹æ¼¼µ¿¿¡ ´ëÇÑ Áø´Ü°ú Ä¡·á°¡ ´õ¿í Àû½Ã¿¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Ȱµ¿°ú ±³À° Ä·ÆäÀÎÀº ½É¹æ¼¼µ¿ ¸ð´ÏÅ͸µ°ú °ü¸®ÀÇ Á߿伺À» °Á¶ÇÏ¸ç ½É¹æ¼¼µ¿ Ä¡·á ±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ³úÁ¹Áß°ú °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§Çؼ´Â Á¶±â ¹ß°ßÀÌ Áß¿äÇϸç, ÀÌ´Â Áø´Ü ¹× ¸ð´ÏÅ͸µ ÅøÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½É¹æ¼¼µ¿ Ä¡·á±â´Â ÀϹÝÀûÀÎ ½ÉÀå ¸®µë Àå¾ÖÀÎ ½É¹æ¼¼µ¿À» Áø´Ü, ¸ð´ÏÅ͸µ ¹× Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â Áß¿äÇÑ ÀÇ·á±â±âÀÔ´Ï´Ù.
Á¦¼¼µ¿±â À̽ÄÇü ½ÉÀå ¸ð´ÏÅÍ Ä«Å×ÅÍ, ÀýÁ¦¼ú, ½ÉÀå ¸®µëÀ» Á¶ÀýÇÏ´Â ½É¹ÚÁ¶À²±â µîÀÌ ÀÌ¿¡ ÇØ´çÇÕ´Ï´Ù. ÁÖ¿ä ¸ñÀûÀº ½ÉÀå ±â´ÉÀ» Á¤»óÀ¸·Î µÇµ¹¸®°í, ³úÁ¹ÁßÀ» ¿¹¹æÇϰí, ½É¹æ¼¼µ¿°ú °ü·ÃµÈ Áõ»óÀ» ¿ÏÈÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ½É¹æ¼¼µ¿ ȯÀÚÀÇ ±Þ¼º±â ¹× Àå±âÀûÀÎ °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ½ÃÀåÀº ½ÉÀå ¸ð´ÏÅÍ, ½É¹æ¼¼µ¿ ÀýÁ¦ Ä«Å×ÅÍ, ¸ÅÇÎ ½Ã½ºÅÛ, ½É¹æ¼¼µ¿ Áø´Ü Ä«Å×ÅÍ, Á¢±Ù Àåºñ, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â Àåºñ, ½É½Ç³» ½ÉÃÊÀ½ÆÄ(ICE) ¹× ±âŸ °ü·Ã Á¦Ç° µî Á¦Ç°º°·Î ºÐ·ùµË´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
°³½Ã³â | 2023³â |
¿¹Ãø³â | 2024-2032³â |
°³½Ã °¡°Ý | 106¾ï ´Þ·¯ |
¿¹»ó °¡°Ý | 279¾ï ´Þ·¯ |
CAGR | 11.5% |
EP ÀýÁ¦ Ä«Å×ÅÍ ºÎ¹®Àº ÀýÁ¦¼úÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀü¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¸ÅÃâÀ» âÃâÇß½À´Ï´Ù. Ä«Å×ÅÍ ¼³°èÀÇ Çõ½Å°ú ¿¡³ÊÁö °ø±Þ ½Ã½ºÅÛÀÇ °³¼±À¸·Î ÀýÁ¦¼úÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚÀÇ ¹üÀ§°¡ ³Ð¾îÁö¸é¼ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµº°·Î ½É¹æ¼¼µ¿ Ä¡·á±â ½ÃÀåÀº ¿Ü·¡ ¼ö¼ú¼¾ÅÍ, º´¿ø, ½ÉÀå¼¾ÅÍ, ±âŸ·Î ³ª´¹´Ï´Ù. Áø´Ü, Ä¡·á ¹× ȯÀÚ ¸ð´ÏÅ͸µÀ» À§ÇØ ´Ù¾çÇÑ ½É¹æ¼¼µ¿ Àåºñ¸¦ ÇÊ¿ä·Î ÇÏ´Â Àü¹® Ä¡·á ¼¾ÅÍ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì ½É¹æ¼¼µ¿ ±â±â ½ÃÀåÀº 2023³â 43¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇϸç, 2024-2032³â ¿¬Æò±Õ 11.3%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ½É¹æ¼¼µ¿ À¯º´·üÀº °í·ÉÈ¿Í »ýȰ½À°üº´ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ºÏ¹ÌÀÇ ³ôÀº ÀÇ·áºñ ÁöÃâÀº ½É¹æ¼¼µ¿ Àåºñ¸¦ Æ÷ÇÔÇÑ Ã·´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¸¦ Áö¿øÇÏ¸ç ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
The Global Atrial Fibrillation Devices Market was valued at USD 10.6 billion in 2023 and is projected to grow at a CAGR of 11.5% from 2024 to 2032. This robust growth is primarily driven by advancements in atrial fibrillation devices, a rising prevalence of AF, an increasing adoption of cardiac ablation procedures, and heightened awareness leading to early diagnosis. The incidence of atrial fibrillation is on the rise globally, making it the most common type of cardiac arrhythmia. Contributing factors include aging populations and increasing rates of obesity, hypertension, and other cardiovascular conditions. With millions affected worldwide, the demand for both diagnostic and treatment devices is escalating.
Increased awareness about atrial fibrillation among patients and healthcare providers has led to more timely diagnoses and treatment. Public health initiatives and educational campaigns highlight the importance of monitoring and managing AF, boosting demand for AF devices. Early detection is crucial to preventing complications like stroke, which in turn drives the use of diagnostic and monitoring tools. Atrial fibrillation devices are essential medical tools used to diagnose, monitor, and treat AFib, a common heart rhythm disorder.
These include catheters for defibrillators implantable cardiac monitors, ablation procedures, and pacemakers that help regulate heart rhythm. Their main goals are to restore normal heart function, prevent strokes, and alleviate AFib-related symptoms. These devices play a vital role in both the acute and long-term management of AFib patients. The market is segmented by product, including cardiac monitors, EP ablation catheters, mapping systems, EP diagnostic catheters, access devices, left atrial appendage closure devices, intracardiac echocardiography (ICE), and other related products.
Market Scope | |
---|---|
Start Year | 2023 |
Forecast Year | 2024-2032 |
Start Value | $10.6 Billion |
Forecast Value | $27.9 Billion |
CAGR | 11.5% |
The EP ablation catheters segment garnered the highest revenue, driven by technological advancements that enhance safety and efficacy in ablation procedures. Innovations in catheter design and improved energy delivery systems have expanded the range of patients who can benefit from ablation, further propelling market growth. In terms of end-use, the atrial fibrillation devices market is divided into ambulatory surgical centers, hospitals, cardiac centers, and others. The hospitals segment led the market in 2023, fueled by the increasing need for specialized treatment centers that require a variety of AF devices for diagnosis, treatment, and patient monitoring.
The North America atrial fibrillation devices market amassed USD 4.3 billion in revenue in 2023 and is expected to grow at a CAGR of 11.3% from 2024 to 2032. This region's high prevalence of AF is influenced by an aging population and a rise in lifestyle-related conditions. High healthcare expenditure in North America supports significant investments in advanced medical technologies, including atrial fibrillation devices, stimulating market growth.